| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
138,140,000 |
| Market
Cap: |
142.28(M) |
| Last
Volume: |
3,241,097 |
Avg
Vol: |
3,286,692 |
| 52
Week Range: |
$0.92 - $1.31 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 807 |
| Guru Rank Value : 1 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Spectrum Pharmaceuticals is a biopharmaceutical company. Co. is engaged in acquiring, developing, and commercializing targeted oncology therapies. Co. has two drugs in late-stage development: Eflapegrastim, which is a long-acting granulocyte colony-stimulating factor for the treatment of chemotherapy-induced neutropenia; as well as Poziotinib, which is an irreversible tyrosine kinase inhibitor under investigation for non-small cell lung cancer tumors with various mutations.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
50,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$22,500 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
0 |
0 |
32,387 |
490,738 |
| Total Sell Value |
$0 |
$0 |
$35,496 |
$343,474 |
| Total People Sold |
0 |
0 |
1 |
7 |
| Total Sell Transactions |
0 |
0 |
1 |
19 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lebel Francois |
Chief Medical Officer |
• – – |
2022-03-15 |
4 |
AS |
$0.71 |
$17,717 |
D/D |
(25,130) |
280,190 |
|
12% |
|
| Gustafson Kurt A |
EVP & Chief Financial Officer |
• – – |
2022-03-15 |
4 |
AS |
$0.71 |
$14,560 |
D/D |
(20,653) |
333,577 |
|
12% |
|
| Lebel Francois |
Chief Medical Officer |
• – – |
2022-02-24 |
4 |
AS |
$0.64 |
$9,413 |
D/D |
(14,708) |
305,320 |
|
12% |
|
| Mcgahan Keith M |
Chief Legal Officer |
• – – |
2022-02-24 |
4 |
AS |
$0.64 |
$9,620 |
D/D |
(15,031) |
275,916 |
|
12% |
|
| Riga Thomas J |
CEO & President |
• • – |
2022-02-24 |
4 |
AS |
$0.64 |
$11,802 |
D/D |
(18,441) |
607,985 |
|
12% |
|
| Gustafson Kurt A |
EVP & Chief Financial Officer |
• – – |
2022-02-24 |
4 |
AS |
$0.64 |
$10,213 |
D/D |
(15,958) |
354,230 |
|
12% |
|
| Lebel Francois |
Chief Medical Officer |
• – – |
2022-02-23 |
4 |
AS |
$0.70 |
$9,467 |
D/D |
(13,466) |
320,028 |
|
20% |
|
| Mcgahan Keith M |
Chief Legal Officer |
• – – |
2022-02-23 |
4 |
AS |
$0.70 |
$9,500 |
D/D |
(13,513) |
290,947 |
|
20% |
|
| Riga Thomas J |
CEO & President |
• • – |
2022-02-23 |
4 |
AS |
$0.70 |
$14,027 |
D/D |
(19,953) |
626,426 |
|
20% |
|
| Gustafson Kurt A |
EVP & Chief Financial Officer |
• – – |
2022-02-23 |
4 |
AS |
$0.70 |
$14,211 |
D/D |
(20,215) |
366,188 |
|
20% |
|
| Vacirca Jeff L |
Director |
– • – |
2022-02-14 |
4 |
A |
$0.68 |
$6,849 |
D/D |
10,000 |
170,244 |
|
- |
|
| Lebel Francois |
Chief Medical Officer |
• – – |
2021-11-09 |
4 |
AS |
$2.18 |
$13,080 |
D/D |
(6,000) |
329,166 |
|
-36% |
|
| Lebel Francois |
Chief Medical Officer |
• – – |
2021-11-08 |
4 |
AS |
$2.20 |
$16,221 |
D/D |
(7,363) |
335,166 |
|
-45% |
|
| Lebel Francois |
Chief Medical Officer |
• – – |
2021-06-23 |
4 |
AS |
$4.00 |
$20,000 |
D/D |
(5,000) |
340,046 |
|
-53% |
|
| Mcgahan Keith M |
Chief Legal Officer |
• – – |
2021-06-22 |
4 |
AS |
$4.16 |
$18,720 |
D/D |
(4,500) |
303,699 |
|
-51% |
|
| Lebel Francois |
Chief Medical Officer |
• – – |
2021-06-22 |
4 |
AS |
$4.09 |
$23,785 |
D/D |
(5,821) |
345,046 |
|
-51% |
|
| Mcgahan Keith M |
Chief Legal Officer |
• – – |
2021-06-21 |
4 |
AS |
$4.27 |
$15,934 |
D/D |
(3,735) |
308,199 |
|
-57% |
|
| Ashton William |
Director |
– • – |
2021-06-18 |
4 |
AS |
$4.24 |
$38,160 |
D/D |
(9,000) |
46,943 |
|
-56% |
|
| Fischer Seth H.z. |
Director |
– • – |
2021-06-18 |
4 |
AS |
$4.24 |
$50,880 |
D/D |
(12,000) |
34,777 |
|
-56% |
|
| Vyas Dolatrai |
Director |
– • – |
2021-06-18 |
4 |
AS |
$4.24 |
$38,160 |
D/D |
(9,000) |
86,346 |
|
-56% |
|
| Welles Bernice R |
Director |
– • – |
2021-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
14,277 |
64,277 |
|
- |
|
| Ashton William |
Director |
– • – |
2021-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
14,277 |
55,943 |
|
- |
|
| Fischer Seth H.z. |
Director |
– • – |
2021-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
14,277 |
46,777 |
|
- |
|
| Vacirca Jeff L |
Director |
– • – |
2021-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
14,277 |
160,244 |
|
- |
|
| Vyas Dolatrai |
Director |
– • – |
2021-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
14,277 |
95,346 |
|
- |
|
658 Records found
|
|
Page 3 of 27 |
|
|
